David A. George of Scripps Laboratories contends that recombinant technologies represent the most responsible approach to securing a steady supply of diagnostic tests. His commentary, published in Genetic Engineering News, directly addresses a growing vulnerability in the sector: reliance on animal-derived or limited biological sources for key assay components.
The argument centers on supply chain resilience. Traditional diagnostic reagents often depend on biological materials from sources such as animal sera or human plasma pools, which face variability in quality, ethical constraints, and potential shortages. Recombinants—proteins or antibodies engineered in cell systems—eliminate that dependence, offering a synthetic, scalable alternative.
Shifting to recombinants could reduce lot-to-lot variation, a persistent issue in assay reproducibility. Greater consistency means fewer failed tests and lower development costs long-term. George suggests that regulatory acceptance is gradually increasing, though adoption still lags due to the capital required to redesign established assays.
No specific timeline or financial figures accompany the recommendation. The article does not name any company currently pursuing a recombinant diagnostic, nor does it cite pending regulatory actions. It reads as a strategic perspective rather than a breaking development.
A key caveat: recombination technology itself carries risks, including immunogenicity and post-translational modifications that may differ from native proteins, potentially affecting test accuracy. Adoption will also require regulators and manufacturers to validate new reference standards.